Cancer Vaccines

Local and Systemic Response Possible with Combination Vaccine

Published in Gene Therapy Weekly, December 9th, 1996

A genetically modified tumor cell vaccine, co-expressing genes for both interferon alpha (IFN-(alpha)) and herpes simplex virus (HSV) thymidine kinase, promotes both a local and systemic antitumor response in a tumor-bearing murine model.

In preliminary research, Italian researchers determined that the transduction of the murine IFN-(alpha)1 gene into various metastatic mouse tumor cells could result in a loss of tumorigenicity and an acquired capacity to induce long-lasting antitumor immunity after injection of these modified cells into immunocompetent syngeneic mice (M. Ferrantini et al., Cancer Res., 1993;53:1107; M. Ferrantini et al., J. Immunol., 1994;153:4604;...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-12-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry